Mutations in the splicing machinery have been implicated in a number of human 18 diseases. Most notably, the U2 small nuclear ribonucleoprotein (snRNP) component 19 SF3b1 has been found to be frequently mutated in blood cancers such as myelodysplastic 20 syndromes (MDS). SF3b1 is a highly conserved HEAT repeat (HR)-containing protein 21 and most of these blood cancer mutations cluster in a hot spot located in HR4-8. Recently, 22 a second mutational hotspot has been identified in SF3b1 located in HR9-12 and is 23 associated with acute myeloid leukemias, bladder urothelial carcinomas, and uterine 24 corpus endometrial carcinomas. The consequences of these mutations on SF3b1
We next tested each LBU-mutant yeast strain for growth defects on solid media.
128 The growth of each strain was assayed at four different temperatures ranging from 16C 129 to 37C. All of the mutant yeast strains were viable at all temperatures when expressing 130 LBU-mutant Hsh155. Moreover, we did not observe any significant differences in cell 131 proliferation between any of the mutants and the WT control at any temperature (Fig. 1C) . 132 We conclude that the LBU-mutant Hsh155 proteins are functional and do not prevent pre-133 mRNA splicing in yeast.
A Subset of LBU Mutants Impact Usage of Non-Consensus Branch Sites

135
We have previously shown that MDS-mutant Hsh155 yeast strains containing 136 substitutions in HR4-7 do not significantly perturb yeast proliferation [9] . Nonetheless, the 137 MDS-mutants impact splicing of introns containing non-consensus BS. To test if the LBU-138 mutants also impact splicing despite the lack of a growth phenotype, we used the ACT1-139 CUP1 reporter transcript to assay splicing in vivo. Splicing of the ACT1-CUP1 pre-mRNA 140 allows for expression of the CUP1 protein and confers Cu 2+ -resistance to sensitized yeast 141 strains ( Fig. 2A) [26]. The degree of Cu 2+ -resistance is directly related to the extent of 142 ACT1-CUP1 pre-mRNA splicing and mRNA formation [26] .
143
We did not observe any differences in Cu 2+ sensitivity between any of the LBU-144 mutant strains or WT yeast when an ACT1-CUP1 reporter was used that contained 145 consensus SS, as shown in Fig. 2B . Nor did we observe any changes in Cu 2+ resistance 146 when the branch point adenosine was substituted in the reporter (A259G; Fig. 2C ).
147 However, in the presence of ACT1-CUP1 reporters harboring a non-consensus, weak BS 148 (A258U) both the Hsh155 V502F and Hsh155 D563G mutants showed lower Cu 2+ resistance 8 149 ( Fig. 2D) . Hsh155 V502F additionally showed lower Cu 2+ resistance with the non-consensus 150 U257C ACT1-CUP1 reporter ( Fig. 2E ).
151
To correlate the observed growth defects with splicing of the ACT1-CUP1 reporter 152 pre-mRNA, we quantified reporter RNA levels by primer extension [9] . We performed 153 primer extension using RNA isolated from strains expressing the WT or Hsh155 V502F
154 Hsh155 D563G LBU-mutants in the presence of WT, A258U, or U257C ACT1-CUP1
155 reporters. We isolated the total RNA from each strain and quantified the relative amount 156 of spliced mRNA. The primer extension assays confirm results from the growth assays 157 with the Hsh155 V502F and Hsh155 D563G mutants showing no detectable defect in splicing 158 of the WT RNA (Fig. 3A) . The Hsh155 V502F LBU-mutant strain was defective in splicing 159 the A258U and U257C reporters, while only a small decrease in splicing of the A258U
160 reporter was observed with the Hsh155 D563G mutant (Fig. 3B,C . We wondered if this would also be true for the Hsh155 V502F mutant in HR9.
168 We combined the V502F mutation with two previously characterized MDS-mutant alleles:
169 H331D and D450G. These two MDS alleles have opposing effects on splicing of pre-170 mRNAs with non-consensus BS: H331D inhibits while D450G promotes their splicing. 9 172 The H331D or D450G mutations still decreased or increased Cu 2+ tolerance; however, 173 the addition of the V502F mutation lowered the degree of Cu 2+ tolerance overall.
174
We also tested additional mutations in the RNA duplex binding site of Hsh155. The 175 K740R and N747A mutations in HR15 also decrease or increase Cu 2+ tolerance in yeast 176 (respectively) when using non-consensus BS reporters [9]. However, these mutations 177 may exert their effects through direct interaction with the U2/BS duplex as opposed to
178 MDS mutation site. The K740R and N747A mutations in HR15 have not been previously 179 studied in combination with those located in distal HR. Therefore, we combined the 180 N747A or K740R mutations in HR15 with the V502F mutation in HR9. The results were 181 similar those observed with the H331D and D450G MDS-mutants in HR5 and HR8 ( Fig.   182 4B-D) . The addition of the V502F mutation lowers the degree of Cu 2+ tolerance in an 183 additive manner in combination with effects from HR15 mutation. From these data, we 184 conclude that the incorporation of multiple mutations in Hsh155 across different HR can 185 result in independent and additive effects on splicing.
Genetic Interaction Between the HR9 V502F Mutant and the Prp2 ATPase
187
We previously identified a genetic interaction between some MDS-mutant alleles 188 of Hsh155 located in HR5 and 8 and the spliceosome ATPase Prp2. Prp2 is responsible 189 for release of Hsh155 and associated U2 proteins from the spliceosome during activation 190 (transition of the B act to B * spliceosome complex) and associates near HR7-8 ( Fig. 5A 
